在肺癌辨识出的新颖融合基因;NOVEL FUSED GENE IDENTIFIED IN LUNG CANCER

摘要

本发明之目的系监定肺癌等癌中可成为预测药剂治疗有效性之指标的突变、提供检测该突变的手段、提供基于该突变，而监定出以具有该突变之基因或由该突变之基因所编码之蛋白质作为标的之药剂能带来治疗效果之癌患者或具有罹癌风险之受验者的手段等。;本发明之解决手段为提供一种属于癌之致病突变(驱动突变)之基因融合的检测方法，其包含检测来自罹癌之受验者之单离样本中之融合多核苷酸或由该融合多核苷酸所编码之多肽的步骤，其中该融合多核苷酸为EZR-ERBB4融合多核苷酸、KIAA1468-RET融合多核苷酸、TRIM24-BRAF融合多核苷酸、CD74-NRG1融合多核苷酸、或SLC3A2-NRG1融合多核苷酸之任一者。;This invention provides a method for detecting a fused gene which causes a responsible mutation (driver mutation) of cancer, comprising a step of detecting a fused polynucleotide or a polypeptide encoded thereby in an isolated sample from a subject with cancer, wherein the fused polynucleotide is any one of EZR-ERBB4 fused polynucleotide, KIAA1468-RET fused polynucleotide, TRIM24-BRAF fused polynucleotide , CD74-NRG1 fused polynucleotide, or SLC3A2-NRG1 fused polynucleotide.